Toward high-resolution 3D-printing of pharmaceutical implants - A holistic analysis of relevant material properties and process parameters.

Biodegradable poly(ether ester) multiblock copolymers High-resolution 3D-printing Process-related material degradation Subcutaneous implants

Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
17 Jun 2024
Historique:
received: 15 03 2024
revised: 15 06 2024
accepted: 16 06 2024
medline: 20 6 2024
pubmed: 20 6 2024
entrez: 19 6 2024
Statut: aheadofprint

Résumé

In this work, filament-based 3D-printing, the most widely used sub-category of material extrusion additive manufacturing (MEAM), is presented as a promising manufacturing platform for the production of subcutaneous implants. Print nozzle diameters as small as 100 µm were utilized demonstrating MEAM of advanced porous internal structures at the given cylindrical implant geometry of 2 mm × 40 mm. The bottlenecks related to high-resolution MEAM of subcutaneous implants are systematically analyzed and the print process is optimized accordingly. Custom synthesized biodegradable phase-separated poly(ether ester) multiblock copolymers exhibiting appropriate melt viscosity at comparatively low printing temperatures of 135 °C and 165 °C were utilized as 3D-printing feedstock. The print process was optimized to minimize thermomechanical polymer degradation by employing print speeds of 30 mm∙s

Identifiants

pubmed: 38897487
pii: S0378-5173(24)00590-8
doi: 10.1016/j.ijpharm.2024.124356
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

124356

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Bianca Brandl (B)

Research Center Pharmaceutical Engineering GmbH, Inffeldgasse 13, 8010 Graz, Austria; Institute of Pharmaceutical Sciences, Pharmaceutical Technology and Biopharmacy, University of Graz, Universitaetsplatz 1, 8010 Graz, Austria.

Simone Eder (S)

Research Center Pharmaceutical Engineering GmbH, Inffeldgasse 13, 8010 Graz, Austria. Electronic address: simone.eder@rcpe.at.

Anbu Palanisamy (A)

InnoCore Pharmaceuticals, L.J. Zielstraweg 1, 9713 GX Groningen, The Netherlands.

Sarah Heupl (S)

FH Upper Austria Research & Development GmbH, Stelzhamerstraße 23, 4600 Wels, Austria.

Ivan Terzic (I)

InnoCore Pharmaceuticals, L.J. Zielstraweg 1, 9713 GX Groningen, The Netherlands.

Matthias Katschnig (M)

Hage3D GmbH, Kratkystraße 2, 8020 Graz, Austria.

Thanh Nguyen (T)

InnoCore Pharmaceuticals, L.J. Zielstraweg 1, 9713 GX Groningen, The Netherlands.

Sascha Senck (S)

FH Upper Austria Research & Development GmbH, Stelzhamerstraße 23, 4600 Wels, Austria.

Eva Roblegg (E)

Research Center Pharmaceutical Engineering GmbH, Inffeldgasse 13, 8010 Graz, Austria; Institute of Pharmaceutical Sciences, Pharmaceutical Technology and Biopharmacy, University of Graz, Universitaetsplatz 1, 8010 Graz, Austria.

Martin Spoerk (M)

Research Center Pharmaceutical Engineering GmbH, Inffeldgasse 13, 8010 Graz, Austria; Institute of Process and Particle Engineering, Graz University of Technology, 8010 Graz, Austria. Electronic address: martin.spoerk@rcpe.at.

Classifications MeSH